Predictive biomarkers for EGFR tyrosine kinase inhibitors in treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
Publication in refereed journal

Full Text

Other information
AbstractKey messages:
1. Of the four potential predictive biomarkers studied, epidermal growth factor receptor (EGFR) gene mutations are the most powerful predictor of the efficacy of EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. They should be tested prior to treatment to select patients who are more likely to benefit from EGFR tyrosine kinase inhibitors.
2. Chemotherapy is a better choice than EGFR tyrosine kinase inhibitors in patients with wild-type EGFR
All Author(s) ListZY Yang, C Mao, DY Zheng, JL Tang
Journal nameHong Kong Medical Journal
Volume Number24
Issue NumberSuppl. 4
Pages34 - 37
LanguagesEnglish-United Kingdom

Last updated on 2020-15-08 at 03:18